Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Salamol CFC-Free MDI Inhaler 100mcg

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Salbutamol sulfate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Salbutamol sulfate

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Effect Salamol contains salbutamol sulfate, which belongs to a group of medicines called beta agonists. Salbutamol is a bronchodilator and works by widening the airways in your lungs to allow air in and out. This helps you to feel less breathless, wheezy or tight-chested. Usage Salamol is used to treat asthma in adults, adolescents and children aged 4 to 11 years. It can also be used to prevent asthma caused by exercise or asthma caused by a reaction to allergens (substances to which you are allergic to e.g. house dust, pollen, dog hair, cat hair, cigarette smoke, etc.) or to treat breathing difficulties associated with reversible airways obstruction (e.g. chronic obstructive pulmonary disease [COPD]). This type of medicine is known as a 'reliever'. You may be using another medicine to prevent you from having an asthma attack ("preventer"). You can safely use your preventer with this medicine. In asthma, fast-acting bronchodilators including Salamol should not be the main or only treatment. It is recommended that Salamol should always be prescribed with an inhaled corticosteroid (anti-inflammatory) medicine.

What you need to know before you take it

e Salamol PE3927V5

Do not use Salamol if you:

  • are allergic to salbutamol or any of the other ingredients of this medicine (listed in section 6).
  • unexpectedly go into early labour (premature labour) or threatened abortion. Warnings and precautions Talk to your doctor, pharmacist or nurse before using Salamol if:
  • your asthma is active (for example you have frequent symptoms or flare ups or limited physical ability). Your doctor may start or increase a medicine to control your asthma such as an inhaled corticosteroid
  • you have high blood pressure
  • you have an overactive thyroid gland
  • you have a history of heart problems such as an irregular or fast heartbeat or angina
  • you are taking xanthine derivatives (such as theophylline) or steroids to treat asthma
  • you are taking water tablets (diuretics), sometimes used to treat high blood pressure or a heart condition. Your inhaler does not have a dose counter. Your inhaler contains enough medicine for 200 puffs only (whether inhaled and/or released into the air for testing) and it contains a propellant gas to deliver the medicine. However, after 200 puffs, your inhaler can continue to spray the gas but without the right dose of salbutamol, so you cannot be sure you will receive any medicine after using 200 puffs. Methods of telling that the inhaler is empty like shaking it, weighing it, or floating it in water, are not reliable. You should consider recording the number of puffs used. You could also consider keeping a back-up inhaler. If you are using more than one inhaler, it is recommended to keep track of the number of puffs used for each inhaler separately. Other medicines and Salamol Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. This includes herbal medicines. Remember to take this medicine with you if you have to go to hospital. In particular tell your doctor, nurse or pharmacist if you are taking:
  • medicines for an irregular or fast heartbeat
  • other medicines for your asthma. If you are having treatment that requires a general anaesthetic, please tell your anaesthetist that you

are taking Salamol. Do not use this medicine for at least six hours before the intended anaesthetic. Salbutamol can reduce the amount of potassium in your blood. If this happens, you may notice an irregular heartbeat, muscle weakness or cramp. This is more likely to happen if you use salbutamol with some medicines used to treat high blood pressure, other medicines used to treat breathing problems (e.g. steroids), stimulants (e.g. xanthines) and long-term laxatives. The following medicines may influence the effect of Salamol:

  • some medicines for the treatment of high blood pressure such as beta-blockers (e.g. propranolol)
  • medicines used to treat heart disease (e.g. digoxin)
  • medicines for the treatment of depression (from the monoamine oxidase inhibitor group e.g. phenelzine or tricyclic antidepressants e.g. amitriptyline or trazodone)
  • water tablets (diuretics)
  • medicines for the treatment of chronic alcoholism (e.g. disulfiram)
  • the anti-microbial drug metronidazole. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines Salamol does not affect your ability to drive or to use machinery. Salamol contains ethanol This medicine contains 3.93 mg of alcohol (ethanol) in each puff (metered dose). The amount in each puff (metered dose) of this medicine is equivalent to 0.1 ml beer or wine. The small amount of alcohol in this medicine will not have any noticeable effects.

How to take it

Salamol Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Salamol should be used as required rather than regularly. If your asthma is active (for example you have frequent symptoms or flare ups, such as breathlessness that makes speaking, eating or sleeping difficult, cough, wheezing, tight chest or limited physical ability), you should tell your doctor right away who may start or increase a medicine to control your asthma such as an inhaled corticosteroid. Tell your doctor as soon as possible if your medicine does not seem to be working as well as usual (for example you need higher doses to relieve your breathing problems or your inhaler fails to give relief for at least 3 hours) as your asthma may be getting worse and you may need a different medicine. If you use Salamol more than twice a week to treat your asthma symptoms, not including preventive use before exercise, this indicates poorly controlled asthma and may increase the risk of severe asthma attacks (worsening of asthma) that can have serious complications and may be life-threatening or even fatal. You should contact your doctor as soon as possible to review your asthma treatment. If you use a medicine against inflammation of your lungs daily, e.g., "inhaled corticosteroid", it is important to continue using it regularly, even if you feel better. The dosage is individually adjusted according to your doctor's instructions, based on previous asthma therapy. For the best results with this medicine you should use it when required to relieve symptoms of asthma and other chest conditions with similar symptoms, such as wheezing, breathlessness and tightness in your chest. Take one puff as a starting dose. This may be increased to two puffs if necessary. To prevent asthma caused by exercise or allergens (e.g. house dust, pollen etc), take two puffs 10-15 minutes before you exercise or before exposure to known allergens. Do not take more than eight puffs in 24 hours. Wait 4 hours between doses. Use in children and adolescents The usual dose for children under the age of 12 years to relieve asthma symptoms such as wheezing,

breathlessness and tightness in the chest, is one puff as a starting dose. This may be increased to two puffs if necessary. The usual dose for children under the age of 12 years to prevent asthma caused by exercise or allergens (e.g. house dust, pollen etc), is one puff 10-15 minutes before exercise or before exposure to known allergens. This can be increased to two puffs if necessary. Children over the age of 12 should refer to the adult dosage instructions above. The usual dose for children under the age of 12 years for regular treatment of asthma (along with regular asthma anti-inflammatory medicine – inhaled corticosteroid) is up to 2 puffs, 4 times a day. Do not take more than eight puffs in 24 hours. Wait 4 hours between doses.

Instructions for use

your doctor or healthcare provider may recommend using the Volumatic® spacer device with the inhaler. Your doctor, nurse, pharmacist, or other healthcare provider should show you how to use the Volumatic® spacer with your inhaler and show you how to care for your Volumatic spacer, and will answer any questions that you may have. It is important that if you are using the Volumatic spacer with your inhaler that you do not stop using it without talking to your doctor or nurse first. If you stop using a spacer device your doctor may need to change the dose of medicine required to control your asthma. Always talk to your doctor before making any changes to your asthma treatment. If you are not using a Volumatic spacer, ignore the steps specifically marked for Patients using a Volumatic spacer and continue to the next step. If you are using a Volumatic spacer follow all the steps below including the ones for Patients using a Volumatic spacer. 1. Take the cap off the inhaler. Make sure the mouthpiece is clean and clear of fluff and dirt.

Important Before using this medicine, please read this leaflet carefully and follow the instructions. The inhaler does not have a dose counter, you can consider recording the number of puffs you are Patients using a Volumatic spacer – Fit the two taking. If you are using more than one inhaler, it is halves of the Volumatic device together. Line up recommended to keep track of the number of doses the notch on one half with the slot on the other for each inhaler separately. (these are marked with small arrows), then press An adult should always supervise children when they the two halves firmly together. use Salamol. Children may need help to use their inhaler. Parents can help by spraying the aerosol 2. Hold the inhaler upright, with when the child begins to breathe in. your thumb on the base and Always remember the following: your first finger on the top of

  • wait four hours between doses. the canister*. Now shake the
  • tell your doctor if your asthma gets worse or if inhaler vigorously up and down. the inhaler does not provide as much relief Patients using a Volumatic spacer – Fit the from your asthma as before. inhaler into the end of the Volumatic, opposite the
  • you should sit or stand upright while taking mouthpiece. Check the mouthpiece of the this medicine. It is important when using this Volumatic inside and outside to make sure that it medicine to hold the inhaler upright as it will is clean. not work if it is not held in this position. 3. Breathe out normally as far as Test spray the inhaler by firing two shots into the air you comfortably can. Then hold before you use it for the first time and also if you the mouthpiece of the inhaler have not used it for a period of five days or more. firmly between your lips. Using the Inhaler 4. Breathe in slowly and deeply. At If you or your child find it difficult to use the inhaler,

160mm

Package leaflet: Information for the patient

salbutamol sulfate

Salamol CFC-Free Inhaler

100 micrograms Pressurised Inhalation Suspension

Template Ref: LF16.1 447 x 160MM Spec. Ref: MPSI092864

Pharma 2289

447mm Printed by Archana Singh, 20 Apr 2026 12:49:25 (UTC +01:00)

page 1 of 3 pages

291155_s1 P Salbutamol Sulfate (SALAMOL CFC Free) UK Inh Sol 100mcg 200 WAT_V3.pdf, Cycle:3, Status:Null

How to store it

Salamol Keep this medicine out of the sight and reach of children. Do not store above 25°C. Do not refrigerate or freeze. If this medicine gets very cold, remove the metal canister from the inhaler and warm it in your hands for a few minutes before you use it. Do not warm the canister in any other way. Pressurised aerosol canister. Do not puncture, break or burn the canister, even if it seems empty. Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.

Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

What Salamol contains

  • The active substance is salbutamol sulfate equivalent to 100 micrograms of salbutamol in each puff (metered dose).
  • The other ingredients are ethanol and the propellant norflurane (HFA-134a). This medicine does not contain any CFCs.
  • This medicine contains fluorinated greenhouse gases.
  • Each inhaler contains 7.5 g of norflurane (HFA-134a) corresponding to 0.01073 tonne CO2 equivalent (global warming potential GWP = 1430). What Salamol CFC-Free Inhaler looks like and contents of the pack The name of your medicine is Salamol CFC-Free Inhaler 100 micrograms Pressurised Inhalation Suspension. Each pack of Salamol contains a single inhaler and canister which supplies 200 metered doses. Marketing Authorisation Holder Norton Healthcare Ltd., T/A IVAX Pharmaceuticals UK, Ridings Point, Whistler Drive, Castleford, West Yorkshire, WF10 5HX, United Kingdom Manufacturer IVAX Pharmaceuticals Ireland IDA Industrial Park, Waterford, Ireland This leaflet was last revised in April 2026. PL 00530/0555

291155_s1

PE3927V5

Like all medicines, this medicine can cause side effects, although not everybody gets them. Contact your doctor immediately if you experience allergic (hypersensitivity) reactions. These include:

  • wheezing, coughing and difficulty breathing
  • rash, swelling of the face and throat and a fall in blood pressure. You might collapse in very rare circumstances. If you experience any of these side effects or if they occur suddenly after using salbutamol you should stop using your medication straightaway and tell your doctor immediately. Allergic reactions to salbutamol are very rare (occurring in less than 1 in 10,000 patients). Other side effects: Common: may affect up to 1 in 10 people
  • feeling tense and getting headaches (which are more likely with higher doses)
  • feeling shaky (muscle tremors)
  • dizziness. Uncommon: may affect up to 1 in 100 people
  • muscle pain (myalgia), muscle cramps.
  • mouth and throat irritation. Rare: may affect up to 1 in 1,000 people
  • a low level of potassium in your blood (if this happens, you may notice an irregular heartbeat, muscle weakness or cramp)
  • increase in lactate levels and acid levels in the blood (you may experience symptoms such as persistent nausea and vomiting, unexplained tiredness, shortness of breath and rapid breathing, cold or blue hands and feet)
  • sleep disturbances and sensing things that are not real
  • rapid or irregular heart beat (tachycardia or palpitations)
  • increased blood flow to your extremities (peripheral dilatation)
  • nausea, vomiting and dry and sore mouth.

Very rare: may affect up to 1 in 10,000 people

  • difficulty in sleeping (insomnia);
  • itching of your skin;
  • trembling (particularly your hands). Not known (frequency cannot be estimated from the available data):
  • chest pain (due to heart problems such as angina). Additional side effects in children
  • sleep disturbances and sensing things that are not real have been reported.
  • hyperactivity. If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist, but do not stop using this medicine unless you are told to do so. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

Salamol CFC-Free Inhaler

soon as possible. Your doctor may want to check your blood potassium levels.

100 micrograms Pressurised Inhalation Suspension

Printed by Archana Singh, 20 Apr 2026 12:49:25 (UTC +01:00)

If you need to use your inhaler before it is dry, shake off any water from the plastic mouthpiece and put the canister back in. Test spray the inhaler by firing two puffs in the air before taking your usual dose. Wash and dry the mouthpiece again as described above. Cleaning the Volumatic spacer Your Volumatic should be cleaned regularly, preferably twice a week. A Gently pull the two halves of the Volumatic apart. Do not take the valve apart. B Wash the two halves of the Volumatic in warm water, which can contain a mild detergent or a sterilising solution of the type used to clean babies' bottles. You can use a soft toothbrush or bottle to help remove any film which forms on the valve or the inside of the Volumatic. As long as the valve still moves when you breathe in and out, this deposit will not affect the working of the Volumatic. C Rinse thoroughly with clean water. Leave the parts at room temperature until they are completely dry. Do not rub the inside of your Volumatic with a cloth or polish as this may cause static electricity which can affect the medicine. Do not put the Volumatic in a heated place to dry more quickly. D Store the Volumatic in the carton to keep clean. Children can assembly the Volumatic and clean it as necessary under adult supervision. The Volumatic may need to be replaced after about 6 to 12 months of use. If you use more Salamol than you should It is important that you take your dose as stated on the pharmacist's label or as advised by your doctor. You should not increase or decrease your dose without seeking medical advice. If you accidentally take a larger dose than recommended, you may notice that your heart is beating faster than usual, that you feel shaky or tense, you may have a headache and your skin may look flushed and feel hot. These effects usually wear off in a few hours, but you should tell your doctor as

salbutamol sulfate

the same time as you start to coming from the top of the inhaler or the sides of breathe in, press the aerosol your mouth you should start again from step 2. canister with your first finger to *Note: Children and people with weak hands may spray the aerosol and release the find it easier to hold the inhaler with both hands, in medicine. Continue to breathe in this case for step 2 put your two first fingers on the slowly and deeply. top of the canister and both thumbs on the base of Patients using a Volumatic spacer – Press down the inhaler. with your finger(s) on the top of the inhaler to ✓ This product can be used with the Volumatic® release one puff of medicine. Straight away take Spacer. Please refer to the instruction leaflet for the one deep steady breath or 5 normal breaths to Volumatic spacer device for further information. make sure that the medicine goes into your lungs. Cleaning the inhaler You do not need to take the Volumatic out of Keeping the plastic mouthpiece clean is very your mouth to breathe out. You should hear the important as it will help prevent your inhaler mouthpiece valve 'click' or rattle as you breathe becoming blocked. You must clean your inhaler once through it. If you do not hear it, tilt the Volumatic a week. up slightly and try again. A To clean your inhaler first 5. Take the inhaler out of your mouth and hold your remove the mouthpiece cap. breath for 10 seconds, or for as long as you comfortably can. Breathe out slowly. Patients using a Volumatic spacer – Take the Volumatic spacer out of your mouth and take your finger from the top of the inhaler. Continue B Remove the metal canister holding your breath for a few seconds, or as long from the plastic mouthpiece. as is comfortable. Breathe out slowly. Do not put the metal 6. If you need more than one puff, wait about one canister into water. minute and then start again from step 2. Put the cap back on the inhaler. 7. You must keep your inhaler clean, especially in C Rinse the inhaler mouthpiece the mouthpiece. This will prevent deposits from and the mouthpiece cap with the aerosol building up. To prevent your inhaler warm running water for at least becoming blocked you must clean it once a week. 30 seconds. 8. What to do if your inhaler stops working properly? It is important to clean your inhaler regularly to prevent deposits from the aerosol building up and blocking the inhaler. If your inhaler does not seem D Shake off any excess water and to be working, it may be that your inhaler has dry the plastic mouthpiece and become blocked and you should clean your inhaler mouthpiece cap thoroughly according to the section "Cleaning the inhaler". (leave to dry overnight if If your inhaler still does not work, return it to possible) but do not use direct your doctor or pharmacist. heat. Put the metal canister back in your inhaler. Replace the cap. Important: Do not rush steps 3 and 4. It is important that you start to breathe in as slowly as possible just Failure to allow the mouthpiece to dry properly before using your inhaler. Practice in front of the will result in an increase in blockage problems. mirror for the first few times. If you see "mist"

page 2 of 3 pages

Frequently asked questions about Salamol CFC-Free MDI Inhaler 100mcg

How do I take Salamol CFC-Free MDI Inhaler 100mcg?

Salamol CFC-Free MDI Inhaler 100mcg comes as inhaler containing 100mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Salamol CFC-Free MDI Inhaler 100mcg?

The active substance in Salamol CFC-Free MDI Inhaler 100mcg is salbutamol sulfate.

Are there equivalent medicines to Salamol CFC-Free MDI Inhaler 100mcg?

Medicines with the same active substance, strength and form include: Asthalin 100 micrograms Inhaler, Salbulin Novolizer 100 micrograms / dose Inhalation Powder. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Salamol CFC-Free MDI Inhaler 100mcg, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Salamol CFC-Free MDI Inhaler 100mcg without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Salbutamol sulfate (16 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

The symptomatic treatment of asthma and other conditions with associated reversible airways obstruction. For relief of wheezing and shortness of breath, Salamol CFC-Free Inhaler should be used on an as required basis.

Prevention of asthma attacks induced by exercise or exposure to allergens.

Salamol CFC-Free Inhaler can be used as relief medication to manage mild, moderate and severe asthma, provided its use does not delay the introduction and regular use of inhaled corticosteroid therapy, where necessary.

Salamol CFC-Free Inhaler is indicated in adults, adolescents and children aged 4 to 11 years. For infants and children under 4 years of age, see section 5.1.

In asthma, short acting beta-2 agonists including Salamol CFC-Free Inhaler should not be the main or only treatment. It is recommended that short acting beta-2 agonists should be prescribed with concomitant inhaled corticosteroid (anti-inflammatory).

4.2. Posology and method of administration

Posology

For optimum results in most patients Salamol CFC-Free Inhaler should be used as required.

Adults (including the Elderly)

Relief of acute asthma symptoms including bronchospasm

One inhalation (100 micrograms) may be administered as a single minimum starting dose. This may be increased to two inhalations (200 micrograms) if necessary.

Prevention of allergen or exercise-induced bronchospasm

Two inhalations (200 micrograms) should be taken 10-15 minutes before challenge.

On demand use of Salamol CFC-Free Inhaler should not exceed 8 inhalations (800 micrograms) in any 24 hours. Inhalations should not usually be repeated more often than every 4 hours. Reliance on such frequent supplementary use, or a sudden increase in dose indicates poorly controlled or deteriorating asthma.

For all patients, four hours should be allowed between each dose.

Paediatric Population

Relief of acute asthma symptoms including bronchospasm

The usual dosage for children under the age of 12 years: one inhalation (100 micrograms). The dose may be increased to two inhalations (200 micrograms) if required.

Children aged 12 years and over: Dose as per adult population.

Prevention of allergen or exercise-induced bronchospasm

The usual dosage for children under the age of 12 years: one inhalation (100 micrograms) before challenge or exertion. The dose may be increased to two inhalations (200 micrograms) if required.

Children aged 12 years and over: Dose as per adult population.

The usual dosage for children under the age of 12 years: up to two inhalations (200 micrograms) 4 times daily.

Children aged 12 years and over: Dose as per adult population.

Patients with Hepatic or Renal Impairment

No need to adjust the dose.

Method of administration

For Inhalation Use.

Salamol administration in children should be supervised by an adult. Children may need help to use their inhaler. Parents can help by spraying the aerosol when the child begins to inhale.

Patients should wait four hours between doses.

Patients should sit or stand upright during inhalation.

It is also important during inhalation that the inhaler be held in an upright position as the inhaler works correctly only in a vertical position.

The aerosol spray is inhaled through the mouth into the lungs. The inhaler should be tested by firing two shots into the air before first use, and if the inhaler has not been used for a period of five days or longer.

Use of the Inhaler

Salamol inhaler may be used with a Volumatic® spacer device by patients who find it difficult to synchronise aerosol actuation with inspiration of breath. Patients should refer to the instruction leaflet for the Volumatic spacer device for further information.

Patients not using a Volumatic spacer should be advised to ignore the steps specifically marked for Patients using a Volumatic spacer and continue to the next step.

Patients using a Volumatic spacer should be advised to follow all the steps below including the ones for Patients using a Volumatic spacer.

1. Patients should remove the cap from the inhaler mouthpiece and make sure the mouthpiece is clean and clear.

Patients using a Volumatic spacer should fit the two halves of the spacer together and then press them firmly together.

2. The inhaler must be held in a vertical position, with the thumb on the base and the index finger on the top of the canister*. Then, patients should shake the inhaler vigorously up and down.

Patients using a Volumatic spacer should fit the inhaler firmly into the end of the spacer, opposite the mouthpiece. Patients should be advised to make sure the mouthpiece is clean.

3. Patients should exhale normally, and place the mouthpiece in their mouth with their lips closed around it.

4. Patients should inhale slowly and deeply and press the canister at the same time to release the spray.

Patients using a Volumatic spacer should press down with their finger(s) on the top of the inhaler to release one puff of medicine. Then, they should take one deep steady breath or 5 normal breaths to make sure that the medicine goes into their lungs.

Patients should be advised they do not need to take the Volumatic out of their mouth to exhale.

They should hear the mouthpiece valve 'click' or rattle as they breathe through it. Otherwise, they should be advised to tilt the Volumatic up slightly and to try again.

5. Patients should remove the inhaler from their mouth and hold their breath for 10 seconds, and then exhale slowly.

Patients using a Volumatic spacer should remove it from their mouth and their finger(s) from the top of the inhaler, and continue to hold their breath for a few seconds, then exhale slowly.

6. If more than one puff is needed, it is important to advise the patient to wait about one minute and start again from step 2. Then, put the cap back on the inhaler.

Patient should be advised to clean the inhaler once a week, especially in the mouthpiece to prevent deposits from the aerosol building up.

Patients should be advised not to rush Steps 3 and 4. It is important that the patient starts to breathe in as slowly as possible just before using the inhaler. If 'mist' is coming from the top of the inhaler or the sides of the mouth of the patient, they should be advised to start again from step 2.

*Note: Children and people with weak hands should be advised they may find it easier by holding the inhaler with both hands.

As with most inhaled medicinal products in pressurised containers, the therapeutic effect of this medicinal product may decrease when the container is cold.

The container should not be punctured, broken or burnt, even when apparently empty.

The metal container must not be put into water.

Full instructions for use of the inhaler and Volumatic spacer are given in the Patient Information Leaflet which should be read carefully by the patient before use.

Cleaning of the Inhaler

Patient must clean the inhaler once a week.

A Remove the mouthpiece cap

B Remove the canister from the plastic mouthpiece. Patient should be advised not to put the canister into water.

C Rinse the inhaler mouthpiece and mouthpiece cap with warm water for at least 30 seconds.

D Shake off any excess water and dry the plastic mouthpiece and mouthpiece cap thoroughly (overnight if possible). It is important to advise the patients not to use direct heat. Patients should put the canister back in the inhaler and replace the cap.

Cleaning of the spacer

The Volumatic should be cleaned regularly, preferably twice a week.

A Patients should gently pull the two halves of the spacer apart. They should be advised not to take the valve apart.

B The two halves of the Volumatic should be washed in warm water, which can contain a mild detergent or a sterilising solution of the type used to clean babies' bottles. Patient can use both toothbrush or bottle brush to help remove any film formed.

C Patients should rinse thoroughly with clean water and leave the parts at room temperature until they are completely dry. Patients should be advised not to rub the inside of the spacer with a cloth or polish as this may cause static electricity which can affect the medicine. Also, they should be advised not to introduce the spacer in a heated place to dry more quickly.

D The Volumatic should be stored in the cartoon to keep clean.

Children can clean their Volumatic when necessary under adult supervision.

Patients should be advised that they may need to replace the Volumatic after about 6 to 12 months of use.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Salbutamol inhalation is contraindicated in treatment of threatened abortion or premature labour.

4.4. Special warnings and precautions for use

Salbutamol should be administered cautiously to patients with thyrotoxicosis, coronary insufficiency, hypertrophic obstructive cardiomyopathy, arterial hypertension, known tachyarrhythmias, concomitant use of cardiac glycosides or diabetes mellitus.

Patients should be instructed in the proper use of the inhaler and their technique checked, to ensure that the active substance reaches the target areas within the lungs.

The inhaler contains enough salbutamol for a total of 200 actuations (puffs). After the 200 actuations (puffs) have been used, the inhaler can when actuated continue to release a spray of propellant which no longer contains the prescribed dose of salbutamol. Methods such as shaking, weighing or submerging inhalers are not accurate for determining that an inhaler is empty of the prescribed dose of salbutamol. To avoid inadvertent use of an empty inhaler, maintaining a record of the number of actuations (puffs) administered to the patient should be considered. Keeping a back-up inhaler could also be considered. If the patient has more than one inhaler, it is recommended to keep track of doses administrated from each inhaler separately (see section 6.6).

Patients who are prescribed regular anti-inflammatory therapy (e.g., inhaled corticosteroids) should be advised to continue taking their anti-inflammatory medication even when symptoms decrease, and they do not require Salamol CFC-Free Inhaler.

The management of asthma should normally follow a stepwise programme, and the patient's response should be monitored clinically and by lung function tests. Increasing use of short-acting inhaled bronchodilators, in particular ß2-agonists to control symptoms, indicates deterioration of asthma control, and patients should be warned to seek medical advice as soon as possible. Under these conditions, the patient's therapy plan should be reassessed. Asthamatic patients whose conditions deteriorates despite salbutamol therapy, or where a previously effective dose fails to give relief for at least three hours, should seek medical advice in order that any necessary additional steps may be taken.

Overuse of short-acting beta-agonists may mask the progression of the underlying disease and contribute to deteriorating asthma control, leading to an increased risk of severe asthma exacerbations and mortality.

Patients who take more than twice a week “as needed” salbutamol, not counting prophylactic use prior to exercise, should be re-evaluated (i.e., daytime symptoms, night-time awakening, and activity limitation due to asthma) for proper treatment adjustment as these patients are at risk for overuse of salbutamol.

The dosage or frequency of administration should only be increased on medical advice.

Patients requiring long term management with Salamol CFC-Free Inhaler should be kept under regular surveillance.

Care should be taken when treating acute asthma attacks or exacerbation of severe asthma as increased serum lactate levels, and rarely, lactic acidosis have been reported after the use of high doses of salbutamol have been used in emergency situations this is reversible on reducing the dose of salbutamol.

Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with salbutamol. Patients with underlying severe heart disease (e.g. ischaemic heart disease, arrhythmias or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease.

Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be either respiratory or cardiac in origin.

Potentially serious hypokalaemia may result from ß2-agonist therapy mainly from parenteral and nebulised administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids, diuretics and by hypoxia. It is recommended that serum potassium levels are monitored in such situations.

In common with other beta-adrenoceptor agonists, salbutamol can induce reversible metabolic changes such as increased blood glucose levels. Diabetic patients may be unable to compensate for the increase in blood glucose and the development of ketoacidosis has been reported. Concurrent administration of glucocorticoids can exaggerate this effect.

As with other inhalation therapies, the potential for paradoxical bronchospasm should be considered. If it occurs the preparation should be discontinued immediately and alternative therapy given. Solutions which are not of neutral pH may rarely cause paradoxical bronchospasm in some patients. Salbutamol and non-selective beta blocking drugs such as propranolol should not usually be prescribed together.

Excipient(s)

Ethanol

The small amount of alcohol in this medicine will not have any noticeable effects.

4.5. Interaction with other medicinal products and other forms of interaction

Propranolol and other non-cardioselective ß-adrenoreceptor blocking agents antagonise the effects of salbutamol, and should not usually be prescribed together.

Monoamine oxidase inhibitors, tricyclic antidepressants, digoxin: risk of increased cardiovascular effects.

Patients should be instructed to discontinue salbutamol at least 6 hours before an intended anaesthesia with halogenic anaesthetics, wherever possible.

Hypokalaemia occurring with β2-agonist therapy may be exacerbated by treatment with xanthines, steroids, diuretics and long-term laxatives.

Because of the content of ethanol, there is theoretical potential for interaction in patients taking disulfiram or metronidazole

4.6. Fertility, pregnancy and lactation

Pregnancy

Salamol CFC-Free Inhaler should only be used in pregnancy in situations where the expected benefit to the mother is thought to outweigh any risk to the foetus.

Salbutamol inhalation is contraindicated in treatment of threatened abortion or premature labour.

Salamol CFC-Free Inhaler

There is no documented evidence of the use of salbutamol formulated with propellant HFA-134a in pregnant women.

Propellant HFA-134a

There is no documented evidence of the use of propellant HFA-134a in pregnant women. Pregnant animals exposed to high levels of HFA-134a showed no evidence of any adverse effects.

Salbutamol

Experience on the use of beta-sympathomimetics during early pregnancy indicates no harmful effect at the doses ordinarily used for inhalation therapy. High systemic doses at the end of pregnancy can cause inhibition of labour and may induce β2-specific foetal/neonatal effects like tachycardia and hypoglycaemia. Inhalation therapy at recommended doses is not expected to induce these harmful side effects at the end of pregnancy.

Breast-feeding

Salamol CFC-Free Inhaler should only be used in lactation in situations where the expected benefit to the mother is thought to outweigh any risk to the neonate.

Salamol CFC-Free Inhaler

There is no documented evidence of the use of salbutamol formulated with propellant HFA-134a in lactating women.

Propellant HFA-134a

There is no documented evidence of the use of propellant HFA-134a in lactating women. Lacting animals exposed to high levels of HFA-134a showed no evidence of any adverse effects.

Salbutamol

Salbutamol may be secreted in breast milk. It is not known whether salbutamol has a harmful effect on the neonate.

Fertility

There is no information on the effects of salbutamol on human fertility.

4.7. Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Based on the MedDRA system organ class and frequencies, adverse reactions are listed in the table below.

Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10000 to <1/1000), very rare (<1/10000; including isolated reports), not known (cannot be estimated from the available data).

System Organ Class

Frequency

Adverse Reaction

Immune system disorders

Very rare

Hypersensitivity reactions (angioedema, urticaria, bronchospasm, hypotension and collapse)

Metabolism and nutrition disorders

Rare

Hypokalaemia ,increased serum lactate levels and acidosis lactic

Psychiatric disorders

Common

Tenseness

Rare

Sleep disturbances and hallucinations (especially in children), hyperactivity in children

Very rare

Insomnia

Nervous system disorders

Common

Tremor muscle, headache, dizziness

Cardiac disorders

Rare

Palpitations, tachycardia

Very rare

Cardiac arrhythmia including atrial fibrillation, supraventricular tachycardia and extrasystoles – especially if used concomitantly with other β2- agonists

Not known

Myocardial ischaemia (see section 4.4)

Vascular disorders

Rare

Peripheral vasodilatation

Respiratory, thoracic and mediastinal disorders

Very rare

Paradoxical bronchospasm (with an immediate increase in wheezing after dosing)

Gastrointestinal disorders

Rare

Mouth irritation, nausea, vomiting, dry mouth, sore mouth

Skin and subcutaneous tissue disorders

Very rare

Pruritus

Musculoskeletal and connective tissue disorders

Uncommon

Myalgia, muscle cramps, mouth and throat irritation

Rare

Muscle cramps

Very rare

Fine tremor (particularly of hands)

As with other inhalation therapies, paradoxical bronchospasm may occur immediately after dosing. Salamol CFC-Free Inhaler should be discontinued immediately, the patient reassessed and treated immediately with another presentation or a different fast-acting inhaled bronchodilator.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Overdosage may result in skeletal muscle tremor, tachycardia, tenseness, headache and peripheral vasodilatation. The preferred antidote for overdosage with salbutamol is a cardioselective ß- adrenoceptor blocking agent. Beta-blocking drugs should be used with caution in patients with a history of bronchospasm, as these drugs are potentially life-threatening.

Hypokalaemia may occur following overdose with salbutamol. Serum potassium levels should be monitored. Lactic acidosis has been reported in association with high therapeutic doses as well as overdoses of short-acting beta-agonist therapy, therefore monitoring for elevated serum lactate and consequent metabolic acidosis (particularly if there is persistence or worsening of tachypnea despite resolution of other signs of bronchospasm such as wheezing) may be indicated in the setting of overdose.

💬 Ask about this leaflet

Ask anything about Salamol CFC-Free MDI Inhaler 100mcg. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →